Equivalence of plasma and serum for clinical measurement of p-tau217: comparative analyses of four blood-based assays
2024
Comparing Blood Tests for Alzheimer's Biomarker
Sample size: 84
publication
Evidence: high
Author Information
Author(s): Chen Yijun, Albert Ally L., Sehrawat Anuradha, Farinas Marissa, Lopez Oscar L., Zeng Xuemei, Cohen Ann D., Karikari Thomas K.
Hypothesis
Is serum p-tau217 as effective as plasma p-tau217 for measuring Alzheimer's disease biomarkers?
Conclusion
Serum p-tau217 performs equivalently as plasma p-tau217 for most assessed assays.
Supporting Evidence
- The ALZpath, Pittsburgh, and NULISA methods showed significantly lower p-tau217 levels in serum compared with plasma.
- Strong correlations (rho >0.8) were observed between plasma and serum p-tau217 pairs.
- Both plasma and serum p-tau217 demonstrated strong classification accuracies to differentiate clinical AD from normal controls.
Takeaway
This study found that blood tests for a specific Alzheimer's marker work just as well in serum as they do in plasma, which is good news for doctors.
Methodology
Paired plasma and serum samples were processed from the same venipuncture collection and assessed with four p-tau217 assays.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website